Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | Zendy

Jessica L. Mega | Zendy; Eugene Braunwald | Zendy; Stephen D. Wiviott | Zendy; JeanPierre Bassand | Zendy; Deepak L. Bhatt | Zendy; Christoph Bode | Zendy; Paul Burton | Zendy; Marc Cohen | Zendy; Nancy CookBruns | Zendy; Keith A.A. Fox | Zendy; Shinya Goto | Zendy; Sabina A. Murphy | Zendy; Alexei N. Plotnikov | Zendy; David J. Schneider | Zendy; Xiang Sun | Zendy; Freek W.A. Verheugt | Zendy; C. Michael Gibson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

Author(s) -

Jessica L. Mega,

Eugene Braunwald,

Stephen D. Wiviott,

JeanPierre Bassand,

Deepak L. Bhatt,

Christoph Bode,

Paul Burton,

Marc Cohen,

Nancy CookBruns,

Keith A.A. Fox,

Shinya Goto,

Sabina A. Murphy,

Alexei N. Plotnikov,

David J. Schneider,

Xiang Sun,

Freek W.A. Verheugt,

C. Michael Gibson

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1112277

Subject(s) - medicine , rivaroxaban , acute coronary syndrome , myocardial infarction , placebo , hazard ratio , stroke (engine) , cardiology , thrombosis , anesthesia , confidence interval , warfarin , atrial fibrillation , mechanical engineering , alternative medicine , pathology , engineering

Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research